PriceTargets.com logo

GoodRx - GDRX Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $5.52
  • Forecasted Upside: 100.83%
  • Number of Analysts: 13
  • Breakdown:
  • 1 Sell Ratings
  • 6 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$2.75 As of 12/4/2025 05:00 PM ET
▲ +0.01 (0.36%)

This chart shows the closing price for GDRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New GoodRx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GDRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GDRX

Analyst Price Target is $5.52
▲ +100.83% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for GoodRx in the last 3 months. The average price target is $5.52, with a high forecast of $7.00 and a low forecast of $4.00. The average price target represents a 100.83% upside from the last price of $2.75.

This chart shows the closing price for GDRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 13 polled investment analysts is to hold stock in GoodRx. This rating has held steady since August 2025, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 12 buy ratings
  • 7 hold ratings
  • 1 sell ratings
Ratings as of
6/12/2024
  • 1 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
9/10/2024
  • 1 strong buy ratings
  • 9 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
12/9/2024
  • 1 strong buy ratings
  • 6 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 1 strong buy ratings
  • 5 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 0 strong buy ratings
  • 5 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 1 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/11/2025JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$6.00 ➝ $5.00
11/10/2025TD CowenLower TargetBuy ➝ Buy$7.00 ➝ $6.00
11/6/2025UBS GroupLower TargetNeutral ➝ Neutral$4.25 ➝ $4.00
11/6/2025MizuhoLower TargetNeutral ➝ Neutral$5.00 ➝ $4.00
10/25/2025Weiss RatingsDowngradeHold (C-) ➝ Sell (D+)
10/8/2025Weiss RatingsReiterated RatingHold (C-) ➝ Hold (C-)
9/27/2025Weiss RatingsReiterated RatingHold (C-) ➝ Hold (C-)
8/11/2025Deutsche Bank AktiengesellschaftReiterated RatingHold ➝ Hold$6.00
8/8/2025Raymond James FinancialDowngradeStrong-Buy ➝ Outperform
5/13/2025UBS GroupLower TargetNeutral ➝ Neutral$6.00 ➝ $5.25
5/9/2025The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$6.00 ➝ $5.00
4/29/2025Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$8.00 ➝ $7.00
4/10/2025Truist FinancialLower TargetHold ➝ Hold$6.50 ➝ $5.50
2/28/2025Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$9.00 ➝ $8.00
1/10/2025CitigroupLower TargetBuy ➝ Buy$7.00 ➝ $6.25
1/8/2025KeyCorpLower TargetOverweight ➝ Overweight$7.00 ➝ $6.00
12/17/2024Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$7.00 ➝ $6.00
12/4/2024MizuhoInitiated CoverageNeutral$5.00
11/13/2024CitigroupLower TargetBuy ➝ Buy$10.00 ➝ $7.00
11/11/2024BarclaysLower TargetOverweight ➝ Overweight$10.00 ➝ $6.00
8/16/2024Royal Bank Of CanadaReiterated RatingOutperform ➝ Outperform$10.00 ➝ $10.00
8/9/2024CitigroupLower TargetBuy ➝ Buy$11.00 ➝ $10.00
8/9/2024UBS GroupLower TargetNeutral ➝ Neutral$9.00 ➝ $8.50
8/9/2024Raymond James FinancialUpgradeOutperform ➝ Strong-Buy$10.00
6/10/2024Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$7.00 ➝ $9.50
5/23/2024Royal Bank Of CanadaUpgradeSector Perform ➝ Outperform$8.00 ➝ $10.00
5/20/2024BarclaysBoost TargetOverweight ➝ Overweight$9.00 ➝ $10.00
5/16/2024TD CowenBoost TargetBuy ➝ Buy$14.00 ➝ $16.00
5/16/2024Raymond James FinancialUpgradeMarket Perform ➝ Outperform$10.00
4/10/2024KeyCorpUpgradeSector Weight ➝ Overweight$9.00
3/25/2024Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$7.50 ➝ $10.00
3/1/2024Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$6.00 ➝ $7.50
3/1/2024UBS GroupBoost TargetNeutral ➝ Neutral$5.00 ➝ $8.00
3/1/2024Royal Bank Of CanadaBoost TargetSector Perform ➝ Sector Perform$7.00 ➝ $8.00
3/1/2024The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$6.50 ➝ $7.50
3/1/2024TD CowenBoost TargetOutperform ➝ Outperform$12.00 ➝ $14.00
3/1/2024Truist FinancialBoost TargetHold ➝ Hold$7.50 ➝ $8.00
3/1/2024BarclaysBoost TargetOverweight ➝ Overweight$8.00 ➝ $9.00
3/1/2024JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$7.00 ➝ $10.00
2/26/2024Leerink PartnrsReiterated RatingOutperform
2/26/2024Leerink PartnersInitiated CoverageOutperform$8.00
1/16/2024Royal Bank Of CanadaBoost TargetSector Perform ➝ Sector Perform$5.00 ➝ $7.00
1/12/2024Truist FinancialBoost TargetHold ➝ Hold$5.50 ➝ $7.50
1/2/2024Bank of AmericaDowngradeBuy ➝ Underperform$8.00 ➝ $4.50
11/17/2023JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$7.00 ➝ $6.00
11/10/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$8.00 ➝ $5.50
11/10/2023Truist FinancialLower TargetHold ➝ Hold$8.00 ➝ $5.50
11/10/2023The Goldman Sachs GroupLower TargetNeutral ➝ Neutral$7.00 ➝ $6.00
11/10/2023Royal Bank Of CanadaLower TargetSector Perform ➝ Sector Perform$8.00 ➝ $5.00
9/14/2023JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$6.00 ➝ $7.00
8/10/2023JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$5.00 ➝ $6.00
8/10/2023GuggenheimBoost TargetBuy ➝ Buy$8.00 ➝ $10.00
8/10/2023Deutsche Bank AktiengesellschaftBoost TargetHold ➝ Hold$6.00 ➝ $8.00
8/10/2023Credit Suisse GroupBoost TargetNeutral ➝ Neutral$7.00 ➝ $8.00
8/10/2023The Goldman Sachs GroupBoost TargetNeutral ➝ Neutral$6.25 ➝ $7.00
8/10/2023Royal Bank Of CanadaBoost TargetSector Perform ➝ Sector Perform$6.00 ➝ $8.00
8/10/2023Evercore ISIBoost TargetIn-Line ➝ In-Line$7.00 ➝ $10.00
8/10/2023CitigroupBoost TargetBuy ➝ Buy$7.00 ➝ $11.00
8/10/2023DA DavidsonUpgradeNeutral ➝ Buy$9.50
8/9/2023Wells Fargo & CompanyBoost TargetEqual Weight ➝ Equal Weight$6.00 ➝ $7.00
7/31/2023TD CowenUpgradeMarket Perform ➝ Outperform$6.50 ➝ $12.00
7/18/2023Truist FinancialBoost TargetHold$6.00 ➝ $7.00
7/17/2023Morgan StanleyBoost Target$6.00 ➝ $8.00
5/11/2023Deutsche Bank AktiengesellschaftLower Target$8.00 ➝ $6.00
5/11/2023Bank of AmericaLower Target$9.00 ➝ $8.00
3/8/2023CitigroupBoost TargetBuy$7.00 ➝ $7.50
3/7/2023Deutsche Bank AktiengesellschaftBoost TargetHold$7.00 ➝ $8.00
3/2/2023Credit Suisse GroupLower TargetNeutral$9.00 ➝ $8.00
3/1/2023Wells Fargo & CompanyBoost TargetEqual Weight$5.50 ➝ $6.00
3/1/2023The Goldman Sachs GroupLower TargetNeutral$8.00 ➝ $7.00
1/18/2023BarclaysLower TargetOverweight$9.00 ➝ $8.00
12/1/2022CitigroupInitiated CoverageBuy$7.00
11/16/2022Truist FinancialLower Target$6.00
11/16/2022CowenLower Target$6.50
11/15/2022DA DavidsonLower Target$5.00
11/10/2022Deutsche Bank AktiengesellschaftLower Target$9.00 ➝ $7.00
11/9/2022The Goldman Sachs GroupLower TargetNeutral$10.00 ➝ $8.00
11/9/2022Morgan StanleyLower TargetEqual Weight$10.00 ➝ $6.00
11/9/2022Royal Bank Of CanadaLower TargetSector Perform$11.00 ➝ $6.00
11/4/2022JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$10.00 ➝ $8.00
10/11/2022BarclaysLower TargetOverweight$13.00 ➝ $9.00
9/15/2022KeyCorpInitiated CoverageSector Weight ➝ Sector Weight
9/7/2022Truist FinancialInitiated CoverageHold$6.50
8/15/2022Evercore ISIBoost Target$12.00
8/12/2022DA DavidsonInitiated CoverageNeutral$8.00
8/10/2022Morgan StanleyLower TargetEqual Weight$10.50 ➝ $10.00
8/9/2022Leerink PartnersBoost TargetMarket Perform$8.00 ➝ $11.00
8/9/2022Credit Suisse GroupBoost TargetNeutral$10.00 ➝ $11.00
8/9/2022The Goldman Sachs GroupBoost TargetNeutral$9.00 ➝ $10.00
8/9/2022Royal Bank Of CanadaBoost TargetSector Perform$6.50 ➝ $11.00
8/9/2022BarclaysBoost TargetOverweight$12.00 ➝ $13.00
7/20/2022BarclaysLower TargetOverweight$15.00 ➝ $12.00
7/18/2022GuggenheimLower TargetBuy$17.00 ➝ $13.00
6/23/2022Royal Bank Of CanadaReiterated RatingSector Perform$8.00 ➝ $6.50
6/22/2022Robert W. BairdLower TargetNeutral$7.00 ➝ $6.00
6/13/2022CowenLower TargetMarket Perform$22.00 ➝ $9.00
6/13/2022CowenLower Target$22.00 ➝ $9.00
6/9/2022The Goldman Sachs GroupDowngradeBuy ➝ Neutral$12.00 ➝ $9.00
6/6/2022Bank of AmericaInitiated CoverageBuy ➝ Buy$11.00
6/1/2022Robert W. BairdDowngradeOutperform ➝ Neutral$10.00 ➝ $7.00
5/20/2022Morgan StanleyLower TargetEqual Weight$19.00 ➝ $10.50
5/12/2022Wells Fargo & CompanyLower Target$20.00 ➝ $9.00
5/11/2022Deutsche Bank AktiengesellschaftLower Target$20.00 ➝ $10.00
5/11/2022Credit Suisse GroupLower Target$22.00 ➝ $10.00
5/10/2022BarclaysLower Target$28.00 ➝ $15.00
5/10/2022Leerink PartnersDowngradeOutperform ➝ Market Perform$33.00 ➝ $10.00
5/10/2022Raymond James FinancialDowngradeOutperform ➝ Market Perform
5/10/2022Royal Bank Of CanadaDowngradeOutperform ➝ Sector Perform$35.00 ➝ $8.00
4/11/2022Wells Fargo & CompanyInitiated CoverageEqual Weight$20.00
4/6/2022GuggenheimInitiated CoverageBuy$24.00
4/5/2022Robert W. BairdBoost Target$17.00 ➝ $23.00
3/17/2022Credit Suisse GroupLower TargetNeutral$27.00 ➝ $22.00
3/15/2022Robert W. BairdUpgradeNeutral ➝ Outperform$17.00
3/8/2022BarclaysLower TargetOverweight$35.00 ➝ $28.00
3/2/2022Morgan StanleyLower TargetEqual Weight$41.00 ➝ $19.00
3/2/2022Raymond James FinancialLower TargetOutperform$45.00 ➝ $30.00
3/2/2022Deutsche Bank AktiengesellschaftLower TargetHold$25.00 ➝ $20.00
3/1/2022JPMorgan Chase & Co.Lower TargetUnderweight$33.00 ➝ $20.00
3/1/2022Evercore ISILower TargetOutperform$47.00 ➝ $28.00
3/1/2022Bank of AmericaLower TargetNeutral$42.00 ➝ $28.00
3/1/2022The Goldman Sachs GroupLower TargetBuy$43.00 ➝ $30.00
3/1/2022Leerink PartnersLower TargetOutperform$49.00 ➝ $33.00
3/1/2022Royal Bank Of CanadaLower TargetOutperform$50.00 ➝ $35.00
3/1/2022BarclaysLower TargetOverweight$43.00 ➝ $35.00
3/1/2022Credit Suisse GroupDowngradeOutperform ➝ Neutral$41.00 ➝ $27.00
3/1/2022CowenDowngradeOutperform ➝ Market Perform$49.00 ➝ $22.00
1/25/2022Deutsche Bank AktiengesellschaftLower Target$44.00 ➝ $25.00
1/7/2022The Goldman Sachs GroupInitiated CoverageBuy$43.00
1/5/2022Robert W. BairdLower Target$40.00 ➝ $34.00
12/21/2021StephensInitiated CoverageOverweight$45.00
12/17/2021Morgan StanleyBoost TargetEqual Weight$38.00 ➝ $41.00
12/1/2021Jefferies Financial GroupInitiated CoverageBuy$47.00
11/15/2021Deutsche Bank AktiengesellschaftLower TargetHold$47.00 ➝ $44.00
11/11/2021BarclaysBoost TargetOverweight$45.00 ➝ $47.00
11/11/2021Leerink PartnersLower TargetOutperform ➝ Outperform$56.00 ➝ $49.00
10/1/2021Deutsche Bank AktiengesellschaftBoost TargetHold$37.00 ➝ $47.00
9/14/2021Credit Suisse GroupBoost TargetOutperform$45.00 ➝ $52.00
8/31/2021BarclaysUpgradeEqual Weight ➝ Overweight$45.00
8/24/2021CowenLower TargetOutperform$44.00 ➝ $42.00
8/15/2021Leerink PartnersInitiated CoverageBuy$56.00
8/13/2021Raymond James FinancialUpgradeMarket Perform ➝ Outperform$45.00
7/2/2021Morgan StanleyBoost TargetEqual Weight$36.00 ➝ $38.00
5/27/2021Robert W. BairdInitiated CoverageNeutral$37.00
5/18/2021Credit Suisse GroupLower TargetOutperform ➝ Outperform$50.00 ➝ $45.00
5/14/2021Leerink PartnersLower TargetOutperform$61.00 ➝ $56.00
5/14/2021Royal Bank Of CanadaLower TargetOutperform$56.00 ➝ $50.00
5/14/2021BarclaysLower TargetEqual Weight$43.00 ➝ $33.00
5/14/2021CitigroupBoost TargetBuy$53.00 ➝ $70.00
5/10/2021CowenLower TargetOutperform$70.00 ➝ $58.00
3/15/2021Credit Suisse GroupBoost TargetOutperform$49.00 ➝ $50.00
3/12/2021BarclaysBoost Target$35.00 ➝ $45.00
3/12/2021Deutsche Bank AktiengesellschaftBoost TargetHold$31.00 ➝ $37.00
3/4/2021Leerink PartnersReiterated RatingBuy$61.00
2/12/2021CowenBoost TargetOutperform$50.00 ➝ $70.00
1/25/2021GuggenheimInitiated CoverageBuy$52.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

0.33 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 9 very positive mentions
  • 10 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 14 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 8 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 5 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 13 very positive mentions
  • 26 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
9/5/2025
  • 16 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 7 very positive mentions
  • 20 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 9 very positive mentions
  • 15 positive mentions
  • 7 negative mentions
  • 1 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 9 very positive mentions
  • 15 positive mentions
  • 7 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

GoodRx logo
GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.
Read More

Today's Range

Now: $2.75
Low: $2.71
High: $2.78

50 Day Range

MA: $3.52
Low: $2.62
High: $5.03

52 Week Range

Now: $2.75
Low: $2.61
High: $5.81

Volume

1,410,791 shs

Average Volume

2,266,217 shs

Market Capitalization

$933.43 million

P/E Ratio

30.56

Dividend Yield

N/A

Beta

1.47

Frequently Asked Questions

What sell-side analysts currently cover shares of GoodRx?

The following Wall Street research analysts have issued reports on GoodRx in the last year: Citigroup Inc., Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., KeyCorp, Mizuho, Morgan Stanley, Raymond James Financial, Inc., TD Cowen, The Goldman Sachs Group, Inc., Truist Financial Corporation, UBS Group AG, Wall Street Zen, Weiss Ratings, and Wells Fargo & Company.
View the latest analyst ratings for GDRX.

What is the current price target for GoodRx?

0 Wall Street analysts have set twelve-month price targets for GoodRx in the last year. Their average twelve-month price target is $5.52, suggesting a possible upside of 100.8%. Wells Fargo & Company has the highest price target set, predicting GDRX will reach $7.00 in the next twelve months. UBS Group AG has the lowest price target set, forecasting a price of $4.00 for GoodRx in the next year.
View the latest price targets for GDRX.

What is the current consensus analyst rating for GoodRx?

GoodRx currently has 1 sell rating, 6 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in GDRX, but not buy more shares or sell existing shares.
View the latest ratings for GDRX.

What other companies compete with GoodRx?

Other companies that are similar to GoodRx include WillScot, PagSeguro Digital, JOYY, CarGurus and JOYY. Learn More about companies similar to GoodRx.

How do I contact GoodRx's investor relations team?

GoodRx's physical mailing address is 233 WILSHIRE BLVD. SUITE 990, SANTA MONICA CA, 90401. The company's listed phone number is 855-268-2822 and its investor relations email address is [email protected]. The official website for GoodRx is www.goodrx.com. Learn More about contacing GoodRx investor relations.